Fruquintinib Combined With Adebrelimab and High and Low Dose Radiotherapy in the Treatment of Second-line and Above Failure MSS Metastatic Colorectal Cancer.

This study tests a combination of three treatments — a targeted drug (fruquintinib), an immunotherapy drug (adebrelimab), and radiation — for people with metastatic colorectal cancer (cancer that has spread) that has stopped responding to standard chemotherapy. The specific cancer type tested is called MSS (microsatellite stable), which is generally harder to treat with immunotherapy alone. **You may be eligible if...** - You are 18 years old or older - You have metastatic colorectal cancer confirmed as MSS type - Your cancer has progressed after receiving at least two prior lines of standard treatment - You are in good physical health (ECOG 0–1) **You may NOT be eligible if...** - You have active autoimmune disease - You have had prior treatment with fruquintinib or adebrelimab - You have serious heart, liver, or kidney problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.